Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Patients had to meet the following criteria to be eligible for the study:~1. Pathologically confirmed adenocarcinoma of the breast.~2. No prior chemotherapy for metastatic breast cancer.~3. Stage IV disease.~4. Measurable disease (must have been ≥ 2.0 cm, except for pulmonary lesions that were well documented on CT scan that were ≥ 1.0 cm).~5. At least 3 weeks since prior cytotoxic chemotherapy (patients should have recovered from all acute effects of such therapy.~6. At least 4 weeks since radiotherapy, with full recovery. The measurable disease was completely outside the radiation portal or there was radiologic or clinical exam proof of progressive disease within the radiation portal.~7. At least 4 weeks since major surgery, with full recovery.~8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~9. Age ≥18 years.~10. Patient had the following blood counts at Baseline:~    * Absolute neutrophil count (ANC) ≥1.5\*10\^9 cells/L~   * Platelets ≥100\*10\^9 cells/L~   * Hemoglobin (Hgb) ≥9 g/dL.~11. Patient had the following baseline blood chemistry levels:~    * Aspartate aminotransferase (AST \[SGOT\]), alanine aminotransferase (ALT \[SGPT\])≥2.5x upper limit of normal (ULN) range~   * Total bilirubin normal~   * Alkaline phosphatase ≥2.5x ULN (unless bone metastasis is present in the absence of liver metastasis)~   * Creatinine ≥1.5 mg/dL.~12. Peripheral neuropathy Grade 0 or 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).~13. If female of childbearing potential, pregnancy test was negative (within 72 hours of the first dose of study drug).~14. If fertile, the patient agreed to use an effective method to avoid pregnancy for the duration of the study.~15. Informed consent had been obtained.~Exclusion Criteria:~Patients who met any of the following criteria were excluded from the study:~1. Prior neo-adjuvant or adjuvant chemotherapy was allowed. No prior chemotherapy for metastatic disease was allowed. If a taxane was part of the adjuvant regimen, at least one year should have transpired since completion of taxane regimen.~2. Cumulative life-time dose of doxorubicin \>360 mg/m\^2. Doxorubicin was allowed as prior neo-adjuvant or adjuvant therapy but not for metastatic disease.~3. Concurrent immunotherapy or hormonal therapy for breast cancer.~4. Parenchymal brain metastases, unless documented to be clinically and radiographically stable for at least 6 months after treatment.~5. Serious intercurrent medical or psychiatric illness, including serious active infection.~6. History of class II-IV congestive heart failure.~7. History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer.~8. Patients who had received an investigational drug within the previous 3 weeks.~9. Patient was enrolled in a different clinical study in which investigational procedures were performed or investigational therapies were administered. Also, a patient was not permitted enroll in such clinical trials while participating in this study.~10. Pregnant or nursing women~11. Patients with prior hypersensitivity to either Taxol or Taxotere.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABI-007 300 mg/m^2 q3w (Type: EXPERIMENTAL): ABI-007 300 mg/m\^2 administered once every third week (q3w).
- ABI-007 100 mg/m^2 weekly (Type: EXPERIMENTAL): ABI-007 100 mg/m\^2 once weekly for 3 weeks followed by 1 week of rest
- ABI-007 150 mg/m^2 weekly (Type: EXPERIMENTAL): ABI-007 150 mg/m\^2 once weekly for 3 weeks followed by 1 week of rest
- Docetaxel 100 mg/m^2, q3w (Type: ACTIVE_COMPARATOR): Docetaxel (Taxotere) 100 mg/m\^2 administered once every third week (q3w).

Based on this trial design, predict the completion outcome and termination type (if applicable).